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Abstract Red blood cells (RBCs) enzymatically produce
nitric oxide (NO) by a functional RBC-nitric oxide syn-
thase (RBC-NOS). NO is a vascular key regulatory mole-
cule. In RBCs its generation is complex and influenced by
several factors, including insulin, acetylcholine, and cal-
cium. NO availability is reduced in end-stage renal disease
(ESRD) and associated with endothelial dysfunction. We
previously demonstrated that, through increased phos-
phatidylserine membrane exposure, ESRD-RBCs aug-
mented their adhesion to human cultured endothelium, in
which NO bioavailability decreased. Since RBC-NOS-de-
pendent NO production in ESRD is unknown, this study
aimed to investigate RBC-NOS levels/activation, NO
production/bioavailability in RBCs from healthy control
subjects (C, N = 18) and ESRD patients (N = 27).
Although RBC-NOS expression was lower in ESRD-
RBCs, NO, cyclic guanosine monophosphate (cGMP),
RBC-NOS Serine1177 phosphorylation level and eNOS/
Calmodulin (CaM)/Heat Shock Protein-90 (HSP90) inter-
action levels were higher in ESRD-RBCs, indicating
increased enzyme activation. Conversely, following RBCs
stimulation with insulin or ionomycin, NO and cGMP
levels were significantly lower in ESRD- than in C-RBCs,
suggesting that uremia might reduce the RBC-NOS
response to further stimuli. Additionally, the activity of
multidrug-resistance-associated protein-4 (MRP4; cGMP-
membrane transporter) was significantly lower in ESRD-
RBCs, suggesting a possible compromised efflux of cGMP
across the ESRD-RBCs membrane. This study for the first
time showed highest basal RBC-NOS activation in ESRD-
RBCs, possibly to reduce the negative impact of decreased
NOS expression. It is further conceivable that high NO
production only partially affects cell function of ESRD-
RBCs maybe because in vivo they are unable to respond to
physiologic stimuli, such as calcium and/or insulin.
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Introduction
Red blood cells (RBCs) represent about 50 % of the human
blood cell fraction and the mean RBC life span of healthy
subjects is about 3 months [1]. In contrast, RBCs from
patients with end-stage renal disease (ESRD) show a
reduced life span, changes in shape, and decreased
deformability [2]. Although anemia in ESRD results
mainly from erythropoietin and iron deficiency, these
metabolic changes, associated to RBC senescence and
aminophospholipid phosphatidylserine (PS) externaliza-
tion, can accelerate clearance of circulating erythrocytes
because of premature suicidal erythrocyte death or eryp-
tosis characterized by PS exposure at the erythrocyte sur-
face [3].
RBCs play an important role in the balance between
generation and scavenging of nitric oxide (NO), which is a
key regulator of vascular homeostasis [4]. Although find-
ings on a functional RBC-NOS in humans are quite con-
tradictory [5], recently it was hypothesized that human
RBCs carry active NOS, producing NO even under nor-
moxic conditions [6, 7]. Of note, NO generation in RBC
has been demonstrated to be influenced by various factors
ex vivo, including insulin [7] and acetylcholine [8].
Recently, we and other authors demonstrated that RBC-
NOS activity regulates several cell functions such as
deformability of RBC membrane and inhibits activation of
platelets. Thus, the microcirculation might be directly
influenced by intracellular erythrocyte NO availability [7,
9, 10].
Interestingly, it has been suggested that the increased
blood viscosity, impaired perfusion at the tissue level, and
the rheological alterations shown in ESRD patients may
play a role in the development of the atherosclerosis pro-
cesses often experienced by these patients [2, 11–14].
Endothelial dysfunction is thought to play a major role
behind the increased cardiovascular risk in ESRD [15], and
alterations in erythrocytes per se and erythrocyte-en-
dothelial cell interactions might contribute to vascular
damage in ESRD as well as in several other diseases [16–
18]. In fact, we have recently demonstrated that in ESRD
patients the appearance of the PS on the RBC surface
increases their adhesion to cultured human endothelial
cells, resulting in decreased endothelial nitric oxide syn-
thase (eNOS) expression and NO release from endothelium
[19–21].
Notably, RBC-NOS expression and activity are
decreased in RBCs from patients with endothelial dys-
function and coronary artery disease [6, 22, 23]. However,
along with the study just mentioned, there are only a few
studies concerning NO production, RBC-NOS expression,
and activation in RBCs from other pathological conditions
[23–25]. Some of them show an increased RBC-NOS
activation in RBCs from sickle cell anemia patients and a
significant increase in cGMP levels within RBCs has also
been found as compared to healthy subjects [25, 26].
Recently, it was shown that NO production was higher in
RBCs from patients with type 2 diabetes than in controls
[27]. The decreased RBC arginase activity could be con-
sidered a potential mechanism for increased RBC NO
production in early diabetes. Thus, the RBC pool may be a
potentially compensatory intravascular compartment for
endothelial dysfunction in diabetes [27]. More recently
Bizjak et al. [28], by a study on age-dependent changes of
rheology and enzymatic properties in RBCs, showed
highest RBC-NOS activation and NO production in old
RBC, suggesting that this is probably required to counter-
act the negative impact of cell shrinkage on RBC
deformability. In addition, they found this effect even more
pronounced in diabetic patients. Interestingly, they further
suggested that, although NO was highly produced, its
bioavailability decreased in old RBC.
Nevertheless, to date, very little is known regarding
basal and stimulated NO and cGMP levels, RBC-NOS
expression and activity in RBCs from ESRD patients.
A few studies suggest that, particularly in platelets and
RBCs, the NO and cGMP levels may be increased in
subjects on dialysis, though the underlying mechanisms
and derived effects are essentially undefined [29–31].
It is well recognized that in physiological conditions the
concentration of cGMP inside cells reflects a balance
between its synthesis and removal. In RBCs the removal of
cGMP involves membrane transporters, including the
multidrug-resistance-associated proteins (MRPs) [32]. In
particular, MRP4 and MRP5 have been detected on RBC
membranes of healthy subjects and both are known to be
implicated in the active efflux of cGMP from RBCs [32].
Based on this, in our study, we aimed to determine basal
and insulin or ionomycin-stimulated NO levels, RBC-NOS
expression and activity, cGMP production and its efflux in
erythrocytes from patients suffering from ESRD and rela-
tive controls. Such knowledge might help define basal and
stimulated nitric oxide synthetic pathway in red blood cells
from end-stage renal disease patients.
Materials and methods
Study population
RBCs were obtained from ESRD patients (N = 27)
recruited from among those presenting at the dialysis
center of the University Hospital of Chieti. RBCs obtained
from age- and gender-matched healthy subjects were used
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as controls (C, N = 18). Table 1 shows the main clinical
and biochemical characteristics of the participants. ESRD
patients had been on regular hemodialysis treatment for
more than 6 months (mean time on dialysis
36.1 ± 29.7 months). The cause of ESRD was nephroan-
giosclerosis in 13 patients, chronic glomerulonephritis in 7,
chronic interstitial nephritis in 4, unknown in 3. Exclusion
criteria included age younger than 18 years or older than
75 years, diabetes mellitus, uncontrolled hypertension,
active infections, malignant or inflammatory disease, blood
transfusion over the past 3 months, iron and folic acid
deficiency, use of drugs that might interfere with erythro-
poiesis (such as angiotensin-converting enzyme inhibitors
and theophylline). Moreover, no drugs affecting NO syn-
thesis or with antioxidant effects were used. All patients
were on stabilized erythropoietin (EPO) dosage, and were
undergoing dialysis three times weekly with a 4-h dialysis
session using bicarbonate dialysate and first-use synthetic
membranes (polysulphone, N = 12; polyacrylonitrile,
N = 15). Healthy control subjects enrolled in the study
were not receiving any medication. Subjects with any
abnormalities on routine physical examination, standard
laboratory tests, ECG, or chest x-ray were not included in
the study. The study protocol was approved by the Ethics
Committee of the University of Chieti, and, in adherence
with the Declaration of Helsinki, written informed consent
was obtained from all subjects taking part in the study.
Erythrocyte preparation
Venous blood samples (4 ml) from healthy subjects and
ESRD patients before hemodialysis were collected as
previously described [22]. After blood sample centrifuga-
tion at 7009g for 5 min at 4 C, the plasma, buffy coat and
top layer of RBCs were removed. Packed RBCs were then
washed three times with Dulbecco’s phosphate buffered
saline 19 (PBS) and re-suspended in PBS at a hematocrit
of 0.01 l/l, thus differently treated for further investigation.
RBC samples were separated via differential centrifugation
and the purity of the RBC preparation was controlled by
fluorescence stain of Glycophorin A in Flow Cytometry
and Immunofluorescence Confocal Microscopy.
Antibodies and materials
RBC-NOS was immunolabeled using a mouse mono-
clonal antibody (eNOS clone 3; BD Transduction Labs,
Lexington, KY), polyclonal antibodies (sc-654 and sc-
8311, Santa Cruz Biotechnology, Inc.) or using anti-
NOS3 antiserum (BD Bioscience). Phospho-eNOS
(Ser1177) was detected using a synthetic peptide, corre-
sponding to aa 1172-1183 (07-428, Upstate Biotechnol-
ogy, Lake Placid, NY) and b-actin using a monoclonal
antibody (A5441, Sigma, St-Louis, MO, USA). Heat
shock protein 90 (HSP90), Caveolin-1 (cav-1), Calmod-
ulin (CaM), and Glycophorin A were immunolabeled
using polyclonal antibodies (respectively, sc-7947, sc-894,
sc-5537, and sc-20628, Santa Cruz Biotechnology, Inc.).
The RBC membrane proteins were probed with anti-
MRP4 (Abcam, Cambridge, UK), anti-MRP5 (SantaCruz
Biotechnology Inc., Santa Cruz, CA), anti-nitrotyrosine
(Millipore, Billerica, MA), anti-S-nitroso-cysteine (Sigma
Chemical Co.), and anti-band 3 (Sigma Chemical Co.).
Secondary antibodies were HRP-conjugated goat anti-
mouse (401253, Calbiochem, La Jolla, CA), goat anti-
rabbit (Rockland), donkey anti-rabbit (Amersham, GE
Healthcare, Chalfont St. Giles, UK), Cy3-conjugated goat
anti-mouse (cod. num. 115 165 146, Jackson Immuno
Research Labs, Inc., West Grove, PA; for chemilumi-
nescence detection), PE-conjugated goat anti-mouse (sc-
2866, Santa Cruz Biotechnology, Inc.), and Alexa 488
goat anti-rabbit (A11034, Molecular Probes, Invitrogen,
Eugene, Oregon, USA; for Immunofluorescence detec-
tion). Insulin (Actrapid HM 100 UI/ml) was from Novo
Nordisk A/S (Bagsvaerd, Denmark). The NO synthase
(NOS) inhibitor N-nitro-L-arginine methyl ester (L-
NAME) and Ionomycin were from Sigma Chemicals (St.
Louis, MO, USA). The NO-reactive dye 4,5-diaminoflu-
orescein diacetate (DAF-2DA) was from Calbiochem
(P.N.251505). The S-Nitroso-N-Acetil-DL-Penicillamide
(SNAP), Ferrous sulfate heptahydrate (FeSO4), and Wil-
mad Quartz (CFQ) EPR tubes (4 mm O.D.) were from
Sigma-Aldrich. The N-methyl-D-glucamine-dithiocarba-
mate (MGD) sodium salt monohydrate was from DBA
(DBA, Milan, Italy).
Table 1 Demographic and
clinical characteristics of the
study population
Control (N = 18) Hemodialysis (N = 27) P value
Gender (M/F) (7/11) (16/11)
Age (years) 57.1 ± 9.4 65.3 ± 11.2 0.143
Systolic blood pressure (mmHg) 121.9 ± 11.4 118.5 ± 17.4 0.655
Diastolic blood pressure (mmHg) 74.1 ± 6.8 73.1 ± 10.4 0.413
Hemoglobin (g/dl) 13.6 ± 1.7 10.9 ± 2.1 \0.001
Creatinine (mg/dl) 1.0 ± 0.2 9.1 ± 2.5 \0.001
Body mass index 23.2 ± 1.4 22.5 ± 2.2 0.577
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Measurement of NO production by EPR
spectroscopy
NO content of RBCs (20 ll of packed and washed C- and
ESRD-RBCs) was measured using electron spin resonance
spectroscopy after in vitro spin trapping as described
elsewhere [33]. Briefly, an aqueous spin trapping solution
Fe2?-(MGD)2 was prepared before each experiment and
RBCs were treated with Fe2?-(MGD)2 (20 ll, 1:1 ratio
with erythrocytes) and incubated for 10 min at 37 C.
Samples were then placed into quartz electron spin reso-
nance tubes and frozen immediately in liquid nitrogen.
Samples were assayed for electron spin resonance spectra
of the relatively stable NO-Fe2?-(MGD)2 adduct. Electron
spin resonance spectra were recorded with a Bruker
ECS106 (Rheinstetten, Germany) spectrometer operating
at X band with 100 kHz modulation frequency at a tem-
perature of 160 K, using 10 mW microwave power to
avoid saturation. Scans were traced with 2.85 G modula-
tion amplitude, 340 G sweep width, and 3356 G central
field as described [34, 35]. Analysis of NO content was
performed with double integration of the NO signal as
described previously [34–36]. NO content of the samples
were expressed in arbitrary units as this method enables a
semi-quantitative assessment of NO content in biological
samples (see for review Csonka et al. [37]).
Western blot analysis
The RBC-NOS enzyme was isolated directly from crude
red cell lysates, immunoprecipitated and analyzed by
Western blot as previously described [38]. As control,
20 lg of human umbilical vein endothelial-cell extracts
(HUVECs) was electrophoretically separated and resolved
together with the red cell lysate. RBC-NOS expression was
defined as red cell eNOS ratio, in which ratio stands for
fold increases of RBC-NOS in C- and ESRD-RBCs versus
control HUVECs.
To evaluate RBC-NOS phosphorylation levels, 400 lg
of protein from erythrocytes lysates was used. Briefly,
proteins were incubated overnight with 2 lg of eNOS
antibody at 4 C, gently rocking; the day after, 40 ll of
50 % slurry protein A/G beads (Santa Cruz Biotechnology,
S. Cruz, CA, USA) were added and incubated for 4 h at
4 C, gently rocking. Immunoprecipitated complexes were
resolved on a 7.5 % SDS-PAGE gel, transferred to nitro-
cellulose membranes and probed with the Phospho-eNOS
antibody (Ser1177; 1:1000) first and then eNOS antibody
(1:1000). Immunoreactive bands were detected using the
ECL system (Amersham, GE Healthcare). The complex
eNOS-HSP90-Calmodulin and Caveolin-1 levels were also
assessed after RBC-NOS immunoprecipitation. Immuno-
precipitated complexes were resolved on a 8 or 12 % SDS-
PAGE gel, transferred to nitrocellulose membrane and
probed with eNOS (1:1000) first and after was probed for
HSP90 (1:1000), Calmodulin (1:1000) and Caveolin-1
(1:1000) and detected as described above.
To determine protein membrane fractions, 600 ll of
packed ESRD- or C-RBCs (both N = 6) was lysed and
centrifuged at 100,0009g for 1 h at 4 C. 50 lg of mem-
brane proteins was resolved by SDS-PAGE and probed
with anti-MRP4 (1:500), anti-MRP5 (1:250), anti-nitroty-
rosine (1:100), anti-S-nitroso-cysteine (1:2000), and anti-
band 3 (1:5000). Protein levels were detected by enhanced
chemiluminescence (Bio-Rad). To evaluate the presence of
nitrated or nitrosated MRP4/MRP5, 500 lg of membrane
proteins was immunoprecipitated with an anti-nitrotyrosine
or an anti-S-nitroso-cysteine antibody (both 1:100) with
20 ll of PureProteome protein A and protein G Magnetic
Beads (Millipore). Immunoprecipitated proteins were sep-
arated by SDS-PAGE and probed with an anti-MRP4 or an
anti-MRP5 antibody, as described above. The densitomet-
ric analysis of Western blots was performed using ImageJ
software (http://rsb.info.nih.gov/ij/) and expressed as arbi-
trary units.
Immunofluorescence confocal microscopy analysis
50 ll of packed and washed RBCs (5 9 108 cells),
obtained as previously described [21], was fixed overnight
in 10 ml of paraformaldehyde 2–4 % in PBS under con-
stant agitation at room temperature (RT). Fixed RBCs were
then washed three times and resuspended in PBS to a
500 ll final volume. For permeabilization, this suspension
was mixed thoroughly in 5 ml of 0.2 % SDS in PBS for
1 min at RT. After removing the SDS by washing with
PBS, the cells were incubated in BSA 1 % for 20 min at
RT. Finally, the erythrocytes were resuspended in BSA
0.1 % solution in PBS (final suspension 50 ll RBCs/250 ll
BSA 0.1 %), and divided into samples of 50 ll for diverse
immune labeling. Each sample was incubated for 2 h at RT
with anti-eNOS antibody, and/or with anti-phospho-eNOS
(Ser1177), or with Anti-Glycophorin A. The secondary
antibodies Cy3 goat anti-mouse and/or Alexa-488 goat
anti-rabbit were incubated for 1 h at RT. Samples for
nuclear staining were meanwhile incubated with TO-PRO
3 IODIDE for 15 min at RT. Negative controls were
obtained, incubating with secondary antibodies alone.
Finally, stained RBCs were resuspended in BSA 0.1 % in
PBS (10 ll RBCs/35 ll tot) and 10 ll of this suspension
was mounted with Slowfade (molecular probe) on poly-L-
lysineted coverslips and then observed under a ZEISS
510META confocal microscope. Images were acquired
using LSM 510 META (rel. 3.0, ZEISS) confocal micro-
scopy software (rel. 3.0, ZEISS).
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Flow cytometry analysis
For Fluorescence Cytometry, packed and washed RBCs were
fixed and permeabilized as described for Immunofluorescence
Confocal Microscopy (10 ll of starting RBCs, corresponding
to 1 9 108 cells, for each final stain). After incubation in
BSA 1 % for 20 min at RT, erythrocytes were resuspended in
BSA 0.1 % and divided into samples of 50 ll for diverse
immune labeling, at final concentrations of 10 ll RBCs/50 ll
suspension. For RBC-NOS determination, each sample was
incubated for 2 h at RT with anti-eNOS antibody, and/or with
anti-phospho-eNOS (Ser1177). The secondary antibodies PE
goat anti-mouse and/or Alexa-488 goat anti-rabbit were
incubated for 1 h at RT. Negative controls were obtained,
incubating only with secondary antibodies. Finally, stained
RBCs were resuspended in PBS (10 ll RBCs/2 ml PBS) and
each sample was analyzed using a FACSCalibur Analyzer
(BD Biosciences). Intracellular protein levels were evaluated
in 10,000 events for each sample by cytofluorimetric analysis
and expressed as a DMean Fluorescence Intensity (M.F.I.)
Ratio. The DM.F.I. Ratio was calculated by subtracting the
value of the M.F.I. of negative events (M.F.I. of a secondary
antibody) from that of positive events, and then dividing by
the M.F.I. of negative events.
Measurement of NO production by DAF-2DA
NO production by RBC-NOS in living erythrocytes was
monitored using the cell-permeable diacetate derivative of
4,5-diamino-fluorescein (DAF-2DA) [39–41] by Flow
Cytometry detection of fluorescent triazolofluorescein,
produced by DAF-2DA intracellular hydrolyzed form
(DAF-2) reaction with NO produced by NOS. The analysis
was done in the presence of L-Arginine (100 lM), and with
stimulation by Ionomycin (2 lM) or Insulin (100 nM) for
10 min, with and without selective NOS inhibitors (L-
NAME, 1 mM). Briefly, 200 ll of packed and washed
RBCs (ESRD and C) was resuspended in EBM Medium-L-
Arginine at a 10 ll RBCs/500 ll final concentration and
incubated with DAF-2DA (10 lM) for 30 min at 37 C in
the dark. In some experiments, L-NAME (1 mM) was
added 45 min before loading with DAF-2DA. After
extensive washes, the erythrocytes were resuspended in
PBS-L-Arginine and stimulated as described above. The
Mean Fluorescence Intensity Ratio (M.F.I. Ratio) was
recorded for 20 min after stimulation, being sampled every
minute using a FACSCalibur Analyzer (BD Biosciences).
Evaluation of intracellular cGMP levels
For intracellular cGMP level evaluation, 500 ll of packed
and washed RBCs (ESRD and C) was treated as described
for the measurement of in vivo NOS activity by DAF-2DA.
Intracellular cGMP was isolated by hydrochloric acid
(0.1 M HCl) precipitation and processed following the
Enzyme immunoassay (EIA) procedure according to the
instructions provided by the supplier (code RPN226, Kit
Biotrak, Amersham Pharmacia Biotec.).
MRP4 ATPase activity
To determine MRP4 ATPase activity, 500 lg of membrane
proteins was immunoprecipitated with an anti-MRP4
antibody (1:100), as detailed in the Western blot analysis
section. Samples (100 lg/protein each) were incubated for
30 min at 37 C in 50 ll of the reaction mix (25 mM Tris
pH 7.0, 3 mM ATP, 50 mM KCl, 2.5 mM MgSO4, 3 mM
dithiothreitol, 0.5 mM EGTA, 2 mM ouabain, 3 mM mol/l
sodium azide). In each set of experiments, a blank con-
taining 0.5 mmol/l sodium orthovanadate was included.
The reaction was stopped by adding 200 ll ice-cold stop-
ping buffer (0.2 % w/v ammonium molybdate, 1.3 % v/v
H2SO4, 0.9 % w/v SDS, 2.3 % w/v trichloroacetic acid,
1 % w/v ascorbic acid). After 30-min incubation at RT, the
absorbance of the phosphate hydrolyzed from ATP was
measured at 620 nm, using a Packard EL340 microplate
reader (Bio-Tek Instruments, Winooski, MA). The absor-
bance was converted into nM hydrolyzed phosphate/min/
mg prot, according to the titration curve previously
prepared.
Statistical analysis
All experiments were repeated at least three times and
results are presented as means ± standard deviation (SD).
Differences between the two population groups (C and
ESRD) and between the different in vitro experimental
conditions were analyzed by Student’s t test. Significance
was defined as a p value less than 0.05.
Results
NO content
We first aimed to assess by electron paramagnetic reso-
nance (EPR) spectroscopy whether the total NO content
was different between RBCs from control subjects and
ESRD patients. As shown in Fig. 1, basal NO content was
significantly higher in ESRD- than in C-RBCs. As expec-
ted, the NO donor (SNAP) significantly increased the NO
content in both C- and ESRD-RBCs as compared to
baseline.
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RBC-NOS expression and phosphorylation levels
We accordingly evaluated the RBC-NOS levels in both
ESRD- and C-RBCs. As shown in Fig. 2, RBC-NOS pro-
tein levels were significantly lower in ESRD- than in
C-RBCs. To evaluate the potential differences in the
mechanisms of NOS activation between ESRD- and
C-RBCs, we determined by immunostaining the Ser1177-
eNOS phosphorylation (ph-eNOS, labeled in green) and
total RBC-NOS levels (labeled in red). As shown in
Fig. 3a, ESRD-RBCs revealed both higher ph-eNOS levels
than C-RBCs and cytoplasmic localization of it (Fig. 3a,
merge panel insets), indicating increased RBC-NOS
translocation to the cytoplasm [42, 43] where the enzyme
becomes more phosphorylated and might also be more
active in ESRD-than C-RBCs. Co-incubation with anti-
bodies directed toward RBC-specific glycophorin A indi-
cated that RBCs were uniformly positive for the eNOS
protein (data not shown). These data were confirmed by
flow cytometry and Western blot analysis (Fig. 3b, left and
right panel, respectively) that showed significantly higher
ph-eNOS levels in ESRD- than C-RBCs (Fig. 3b left panel,
DM.F.I. 7 ± 0.9 and 5 ± 0.1, respectively).
RBC-NOS signaling complex activation
Next, we assessed the interaction levels of RBC-NOS with
caveolin-1 (cav-1), calmodulin (CaM), and heat shock
protein-90 (HSP90), known to be involved in the eNOS
activation process in endothelial cells [42] and conjec-
turally inside erythrocytes [43]. As shown in Fig. 4, the
CaM/HSP90/eNOS association was significantly higher in
ESRD- than in C-RBCs (Fig. 4a, 1.7 ± 0.06-fold and
0.93 ± 0.06-fold, respectively, and Fig. 4b, 2.55 ± 0.05-
fold and 1.55 ± 0.04-fold, respectively), while cav-1 was
significantly less co-immunoprecipitated with RBC-NOS
in ESRD- than C-RBCs (Fig. 4c, 0.63 ± 0.05-fold and
1.02 ± 0.2-fold, respectively).
NO production in basal and stimulated RBCs
To further characterize RBC-NOS activity in ESRD-RBCs,
we evaluated NO production in intact erythrocytes at
baseline and after time-dependent stimulation (0–10 min)
with insulin (100 nM) or ionomycin (2 lM), known to
activate eNOS respectively via phosphorylation- and cal-
cium-dependent pathways [42]. All the experiments were
performed in the presence or absence of L-NAME, a
specific inhibitor of NOS activity. Interestingly, as shown
in Fig. 5a (right panel), the fluorescence of 4,5-diamino-
fluorescein (DAF-2), which depends on the amount of
intracellular NO levels, proved to be increased in both C-
and ESRD-RBCs after insulin stimulation, although its
effect was significantly greater in C- than ESRD-RBCs. In
parallel, ionomycin (Fig. 5a, left panel) significantly
increased DAF-2DA fluorescence in both C- and ESRD-
RBCs and, likewise insulin, NO production was again
significantly higher in C-than ESRD-RBCs. Moreover, for
both C- and ESRD-RBCs, pre-incubation with L-NAME
fully inhibited both insulin- and ionomycin-stimulated
RBC-NOS activity, demonstrating a NOS-dependent pro-
duction of NO. As expected and according to the EPR data,
Fig. 1 NO content. EPR spectroscopy measurement of NO content in
C- (N = 6) and ESRD-RBCs (N = 5) at baseline (basal) or in
presence of the NO donor SNAP (10-4 M). Results are presented as
means ± SEM of at least three separate experiments and are
expressed as arbitrary units (AU). #p = 0.002 basal ESRD versus
Basal C. *p\ 0.001 SNAP versus Basal
Fig. 2 RBC-NOS expression levels. eNOS protein expression in C-
and ESRD-RBCs as measured by Western blot analysis. Results are
presented as means ± SD of at least three separate experiments and
are expressed as a red cell eNOS ratio. Ratio stands for fold increases
of RBC-NOS in C- and ESRD-RBCs versus control HUVECs.
*p\ 0.05 ESRD versus C
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basal NO levels were significantly higher in ESRD- than
C-RBCs (Fig. 5a).
cGMP levels in basal and stimulated RBCs
We went on to measure intracellular cGMP levels in both
C- and ESRD-RBCs. As shown in Fig. 5b, basal cGMP
levels were significantly higher in ESRD- than C-RBCs.
Both insulin and ionomycin treatments significantly
increased cGMP levels in C-RBCs, while in ESRD-RBCs
cGMP levels proved to be significantly lower than basal
condition. As expected, pre-incubation with L-NAME
inhibited both insulin- and ionomycin-increased intracel-
lular cGMP content, both in C- and in ESRD-RBCs.
cGMP transporter (MRP4 and MRP5) expression,
nitration and/or nitrosation levels and activity
in RBC membrane fractions
The bioavailable NO activates soluble guanylate cyclase
(sGC) with a subsequent increase in cGMP content.
However, we supposed that the observed cGMP increase in
ESRD-RBCs might also be ascribed to intracellular accu-
mulation of it. For this purpose, we examined the expres-
sion of MRP4 and MRP5 transporters, known to be capable
of transferring cGMP out of erythrocytes. As shown in
Fig. 6, MRP4 and MRP5 were detected in RBC membrane
fractions with no significant differences between C- and
ESRD-RBCs.
Since it is known that nitration or nitrosation may lead
to inactivation of these transporters, we evaluated their
levels. The overall pattern of nitrated and nitrosated
membrane proteins was similar (Supplementary Fig. S1),
although specific bands were slightly more nitrated and
nitrosated in ESRD- than C-RBCs. Notably, MRP4 was
significantly more nitrated on tyrosine and more nitrosated
in cysteine in ESRD- than C-RBCs (Fig. 7). Neither
nitration nor nitrosation was detected on MRP5 in either C-
or ESRD-RBCs (data not shown).
Hence, we measured the ATPase activity of MRP4 which
proved significantly lower in ESRD- than C-RBCs (Fig. 8),
suggesting impaired cGMP efflux from ESRD-RBCs.
Fig. 3 RBC-NOS phosphorylation levels. a eNOS and ph-eNOS
immunolocalization in C- and ESRD-RBCs. eNOS (labeled in red)
and ph-eNOS (labeled in green) were detected in RBCs using
immunofluorescence confocal microscopy (original magnification
9400, bars indicate 10 lm). The higher magnification (inset in merge
panels, original magnification 91000, bars indicate 10 lm) shows in
detail the subcellular localization of eNOS and ph-eNOS. b Ser1177-
eNOS phosphorylation levels (ph-eNOS) as measured by flow
cytometry and expressed as a DMean Fluorescence Intensity
(M.F.I.) Ratio. (*p\ 0.05 ESRD- vs. C-RBCs). c Representative
Western blot of eNOS and ph-eNOS immunoprecipitate levels in
three C- and ESRD-RBC samples. Samples were probed for ph-eNOS
first and then re-probed for total NOS. d eNOS phosphorylation levels
as measured by Western blot. The ratio of ph-eNOS co-immunopre-
cipitation with eNOS is expressed as a relative intensity of the bands.
Results are presented as means ± SD of at least three separate
experiments. (*p\ 0.03 ESRD- vs. C-RBCs). (Color figure online)
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Discussion
In this study, we have, for the first time, determined RBC-
NOS expression and activity, NO and cGMP levels in
erythrocytes in patients suffering from end-stage renal
disease.
Our results showed that both control and ESRD ery-
throcytes express functional RBC-NOS and, notably, the
level of this last was significantly lower in ESRD- than
C-RBCs. Surprisingly, although we were expecting a par-
allel decrease in RBC-NOS activity, we found that its
activation, NO, and cGMP levels were all significantly
greater in ESRD- than C-RBCs.
Moreover, intracellular NO and cGMP levels were
increased in both C- and ESRD-RBCs after insulin or
ionomycin stimulation, although their effects were sig-
nificantly greater in C- than ESRD-RBCs. This indicates
that the uremic condition might reduce the RBC-NOS
response to these stimuli possibly due to biochemical or
metabolic alterations such as increased insulin resistance
[44]. As mentioned above, in our study, we found that
basal RBC-NOS was significantly more activated in ure-
mic erythrocytes than in controls. There are indeed
studies indicating that, under several pathological condi-
tions, certain mechanisms that compensate deficient NO
production may be activated [25, 28, 45]. In particular,
these mechanisms include plasma oxidative stress, a
condition existing in uremia [46, 47], which can cause a
paradoxical increase in RBC-NOS activity [48]. In addi-
tion, shear stress, by increasing Ca2? influx into RBC
cytoplasm as well as ph-eNOS levels, may lead to RBC-
NOS activation through a mechanism involving cav-1,
HSP90, and CaM [43, 49].
Again, we have previously demonstrated that phos-
phatidylserine exposure on the surface of RBC from ESRD
patients increases RBC-human umbilical vein endothelial
cell interactions, thus suggesting that modified ESRD-
RBCs might also show abnormal RBC-NOS activation,
possibly due to enhanced cytoadherence and locally
increased mechanical forces [20, 49, 50].
Fig. 4 RBC-NOS signaling
complex activation. Left C-
(gray bars N = 18) and ESRD-
RBCs (black bars N = 27); the
ratios of CaM, HSP90 or cav-1
co-immunoprecipitation with
eNOS (a *p\ 0.03;
b *p\ 0.01 or c *p\ 0.05 all
ESRD- vs. C-RBCs,
respectively) are expressed as a
relative intensity of the bands.
Results are presented as means
± SD of at least three separate
experiments. Right
representative
immunoprecipitation of
a eNOS/CaM, b eNOS/HSP90
or c eNOS/cav-1 in three C- and
ESRD-RBC samples
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Subsequently, we demonstrated that RBC-NOS from
ESRD-RBCs disrupted the eNOS/cav-1 interaction on the
plasma membrane and increased CaM binding, possibly
activating the enzyme and inducing translocation to the
cytoplasm where eNOS bound to HSP90 became more
phosphorylated and synthesized more NO (Figs. 3, 4) [42,
51–53].
Although NO generated by red cell NOS may not rep-
resent a physiologically important fraction of total NO
bioavailability [54], in this instance we may hypothesize
compensatory NO synthesis on the part of uremic RBCs
which are, of course, an important factor contributing to
local hemodynamic. Thus, the relatively fast increase in
intracellular NO concentration in response to local
increased mechanical forces would be expected to improve
RBC deformability and blood flow, especially at the
microcirculatory level [7, 9, 54].
Additionally, the demonstrated increase in uremic RBC-
NOS activation proved similar to that found in erythrocytes
from patients with sickle cell anemia [25], there being
significant increased RBC-NOS activity, though the enzyme
expression was slightly lower than in healthy subjects.
Patients with ESRD invariably suffer from anemia,
which is considered to result in large part from impaired
renal EPO and subsequent decrease in erythropoiesis, and
to a lesser extent from accelerated eryptosis [3].
On this basis, and since it has been shown that the use of
EPO might lead to higher RBC-derived NO levels [55, 56],
one might speculate that the EPO treatment used to break
down the anemic state in ESRD patients might be one of
the mechanisms involved in the increased RBC-NOS
activity observed. To this end we performed some exper-
iments in which RBC-NOS expression and activation of it
by phosphorylation in ESRD-RBCs proved comparable
among patients treated with EPO or not (ph-eNOS: DM.F.I.
ratio 6 ± 0.5 and 5.8 ± 0.4, six treated and six untreated
patients, respectively).
Again, since EPO administration had been shown to
produce in the circulation an immediate increase in the
number of immature erythrocytes known as reticulocytes
Fig. 5 Basal and stimulated NO production and cGMP levels. C- and
ESRD-RBCs (N = 18 and N = 27, respectively) at baseline (Basal)
and stimulated with insulin (Ins, 100 nM) or ionomycin (Ion, 2 lM)
in the presence or absence of the NOS inhibitor L-NAME (1 mM,
Ion ? L-N or Ins ? L-N). Results are presented as means ± SD of at
least three separate experiments. a NO production measured by flow
cytometry and expressed as a DAF-2DA Mean Fluorescence Intensity
Ratio (M.F.I. Ratio). Left #p\ 0.05 basal C- vs. basal ESRD-RBCs;
*p\ 0.05 Ins vs. basal C- and ESRD-RBCs; p\ 0.05 Ins C- vs. Ins
ESRD-RBCs. Right #p\ 0.05 basal C- vs. basal ESRD-RBCs;
*p\ 0.03 Ins vs. basal C- and ESRD-RBCs; p\ 0.05 Ins C- vs. Ins
ESRD-RBCs. b cGMP levels measured by EIA assay in C- (gray
bars) and ESRD-RBCs (black bars). *p\ 0.03 Ins- vs. basal
C-RBCs; **p\ 0.05 Ion- vs. basal C-RBCs; #p\ 0.01 basal ESRD-
vs. basal C-RBCs; p\ 0.05 Ins- vs. basal ESRD-RBCs; p\ 0.05
Ion- vs. basal ESRD-RBCs
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[57], in order to ascertain that NOS activity did not derive
from reticulocytes, we measured the number of these last.
We found that there were no more than 5 % of reticulo-
cytes in patients, whether treated with EPO or not, and this
was comparable to healthy subjects. Thus, although our
ESRD patients were on stabilized EPO treatment, we can
rule this out from the potential mechanisms able to activate
RBC-NOS in ESRD-RBCs.
Fig. 6 MRP4 and MRP5
membrane expression levels.
a Representative Western blot
analysis from C- (N = 6) and
ESRD-RBCs (N = 6)
membrane extracts. Band 3 was
used as control of equal protein
loading. b Histograms represent
MRP4/band 3 and MRP5/band 3
density ratio expressed as
arbitrary unit. Results are
presented as means ± SD of at
least three separate experiments
Fig. 7 MRP4 nitration and
nitrosation levels. C- (N = 6)
and ESRD-RBCs (N = 6)
membrane extracts were
immunoprecipitated with an
anti-nitrotyrosine (NOTyr) or an
anti-S-nitrosocysteine (NOCys),
then probed with anti-MRP4.
a Representative Western blot
analysis. b Histograms
representing NOTyr-MRP4 and
NOCys-MRP4 levels. Results
are presented as means ± SD of
at least three separate
experiments. *p\ 0.01 ESRD-
vs. C-RBCs
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Here, we also found increased cGMP levels in RBC
from ESRD patients as compared to healthy control.
Interestingly, Reis et al. [58] demonstrated that transport of
L-arginine is activated in erythrocytes from ESRD patients
irrespective of their nutritional status, thus resulting in a
potential activation of RBC NO synthesis in uremia. Thus,
the data presented here as well as data from an independent
human study published several years ago [31] fully support
this hypothesis.
Besides these mechanisms, the cGMP concentration
achieved in RBCs results from a balance between synthesis
and removal, so that the removal rate is as important as the
production rate. It has been demonstrated that cGMP pro-
duced within human erythrocytes can be eliminated by
phosphodiesterases [59] or by active efflux transporters
[60]. Wu et al. [32] found that different blood donors
express different amounts of both MRP4 and MRP5 on
their RBCs. These differences in expression were reflected
in different cGMP uptake rates in inside-out erythrocyte
membrane vesicles. Since RBCs from uremic patients
show several modifications in the RBC membrane protein
composition and function [61, 62], this might compromise
cGMP efflux through the membrane transporters. Our study
is the first to have examined the levels of expression,
nitration and/or nitrosation, and activity of MRP4 and
MRP5 transporters. Although they proved equally expres-
sed in C- and ESRD-RBC membranes (Fig. 6), MRP4 was
significantly more nitrated on tyrosine and more nitrosated
on cysteine in ESRD- than in C-RBCs (Fig. 7), while
neither nitration nor nitrosation was detected on MRP5 in
either group. In addition, the ATPase activity of MRP4 was
significantly lower in ESRD- than C-RBCs (Fig. 8), sug-
gesting possible impaired efflux of cGMP across the
ESRD-RBC membrane.
In conclusion, since whether and how erythrocyte RBC-
NOS activity and/or signaling is potentially involved in
changes of RBC function in uremia has not been investi-
gated so far, we here thought to document, for the first
time, a significant increase of basal enzymatic NO pro-
duction and accumulating cGMP levels, possibly to coun-
teract the reduction in RBC-NOS expression within RBCs
from uremic patients. We could further speculate that high
NO production only partially affects cell function of
ESRD-RBCs maybe because in vivo they are unable to
respond to physiologic stimuli, such as calcium and/or
insulin.
Thus, although further development and functional
characterization of the mechanisms here described are
needed, this study may help better define the role of RBC-
NOS in the regulation of erythrocyte function in uremia
and possibly to develop a strategy to improve RBC func-
tions and extend cell life span in uremic erythrocytes.
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